Stem cells from umbilical cords may reduce scars after skin grafts

NCT ID NCT05984628

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This trial tests whether injecting human umbilical cord stem cells into skin graft donor sites can speed healing and reduce scarring. Participants are adults aged 18 to 60 who need medium-thickness skin grafts for scars, tumors, or fresh wounds. Half receive the stem cell injection, while the other half gets a placebo. Researchers will compare wound closure time and scar quality over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
human umbilical cord mesenchymal stem cells injected into the wound area
What this could lead to
If it works, this could lead to faster healing and less scarring for people who need skin grafts.
What could go wrong
This is an early-stage trial with a small number of participants, so results may not apply to everyone. Stem cell injections carry risks like infection or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 88 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2021

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients between 18 and 60 years old with extensive scars, large benign tumors, or fresh wounds on the body surface. 2. Patients who undergo medium-thickness skin graft surgery (donor site can be from the thigh, abdomen, or back). 3. Participants who have a thorough understanding of the study objectives, significance, implementation plan, potential benefits, risks involved, measures to address risks, and the rights and obligations of the subjects (including privacy protection and the right to withdraw), and are willing to participate in this clinical study and can cooperate effectively. Exclusion Criteria: Participants who meet any of the following criteria are not suitable for inclusion: 1. Hypertension, hypotension, heart disease (including history of myocardial ischemia, coronary heart disease, myocarditis). 2. Liver or kidney dysfunction. 3. Infectious diseases (including viral hepatitis, syphilis, HIV/AIDS, etc.). 4. Venous thrombosis, thoracic or abdominal aortic aneurysm, aortic dissection. 5. Blood disorders (abnormal coagulation function, anemia, leukemia, polycythemia vera, aplastic anemia, etc.). 6. Allergic conditions (urticaria, bronchial asthma, history of allergic reactions to two or more drugs or foods). 7. Respiratory system diseases (chronic bronchitis, emphysema, bronchiectasis, respiratory failure, chronic obstructive pulmonary disease, interstitial pneumonia). 8. Digestive system diseases (severe gastric or duodenal ulcers, chronic gastritis, chronic pancreatitis). 9. Urinary system diseases (chronic urinary tract infections, nephritis, nephrotic syndrome). 10. Endocrine system diseases (hyperthyroidism, diabetes, acromegaly, pituitary diseases, adrenal diseases, diabetes insipidus). 11. Organic neurological disorders or psychiatric illnesses (encephalitis, sequelae of traumatic brain injury, epilepsy, schizophrenia, hysteria, depression, severe insomnia, neurasthenia). 12. Chronic skin diseases (especially infectious, allergic, and inflammatory systemic skin diseases, such as extensive eczema, pemphigus, pemphigoid). 13. Autoimmune diseases and collagen diseases (such as systemic lupus erythematosus, dermatomyositis, scleroderma). 14. History of long-term smoking, alcohol abuse, or drug addiction. 15. History of major surgeries (such as gastric, lung, splenic, renal, or liver resection). 16. History of other significant malignant tumors. 17. Blood donation or organ transplantation within the past 5 years. 18. Pregnancy, lactation, menstrual period, or within 1 year after termination of pregnancy. 19. Previous circumstances of being rejected for voluntary blood donation. 20. Other situations deemed unsuitable for participation in this study by the investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Scar, hypertrophic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cicatrix, Hypertrophic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chenxiaosong

    RECRUITING

    Fujian, Fuzhou, 350001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.